₹58900
(Inclusive of all Taxes)
Get Free delivery (₹99) with



Hemlibra 30 mg Injection is used to prevent or reduce bleeding episodes in individuals with haemophilia A. Haemophilia A is a genetic bleeding disorder caused by a deficiency or absence of clotting factor VIII that impairs blood clotting ability. It leads to prolonged bleeding episodes, often following injuries or surgeries, and can cause spontaneous internal bleeding.
Hemlibra 30 mg Injection contains Emicizumab, which works by replicating the function of factor VIII, a crucial protein for blood clotting. It connects activated factor IX and factor X, promoting effective clot formation in individuals with haemophilia A. This process helps prevent and minimize bleeding episodes, including in patients with factor VIII inhibitors.
The dose and duration of treatment with Hemlibra 30 mg Injection may vary depending on your medical condition. The common side effects of Hemlibra 30 mg Injection include redness, tenderness, warmth, or itching at the injection site, as well as joint pain and headache. Most of these side effects resolve gradually over time. However, consult the doctor if any of these persist or worsen.
Inform your doctor if you are pregnant or planning pregnancy or breastfeeding before treatment with Hemlibra 30 mg Injection. Hemlibra 30 mg Injection is safe for children if prescribed by the doctor. Avoid alcohol consumption while taking Hemlibra 30 mg Injection to prevent unpleasant side effects. Hemlibra 30 mg Injection may cause dizziness; therefore, avoid driving or operating heavy machinery unless fully alert. Inform your doctor about all the medicines you are taking and about your pre-existing health conditions.
Hemlibra 30 mg Injection is used to prevent or reduce bleeding episodes in individuals with haemophilia A (a genetic bleeding disorder). The detailed uses of Hemlibra 30 mg Injection are as follows:
Hemlibra 30 mg Injection contains Emicizumab, which belongs to a group of medications called Monoclonal antibodies. It is used to prevent or reduce bleeding episodes in individuals with haemophilia A (a genetic bleeding disorder). Hemlibra 30 mg Injection replicates the function of factor VIII, a crucial protein for blood clotting. It connects activated factor IX and factor X, promoting effective clot formation in individuals with haemophilia A. This process helps prevent and minimize bleeding episodes, including in patients with factor VIII inhibitors.
Consult your doctor
The interaction of alcohol with Hemlibra 30 mg Injection is unknown. If you have any concerns, please discuss them with your doctor.
Caution
Please inform your doctor if you are pregnant or planning to become pregnant; your doctor will administer Hemlibra 30 mg Injection only if the benefits outweigh the risks. Also, women who are capable of becoming pregnant must use effective contraception during and for a minimum of 6 months after stopping treatment with Hemlibra 30 mg Injection.
Consult your doctor
It is unknown if Hemlibra 30 mg Injection passes into breast milk. Therefore, please inform your doctor if you are breastfeeding. Your doctor decides based on the benefits and risks of Hemlibra 30 mg Injection to the mother and baby.
Safe if prescribed
Hemlibra 30 mg Injection usually does not affect your ability to drive or operate machines.
Consult your doctor
Please inform your doctor if you have liver impairment/liver disease before receiving Hemlibra 30 mg Injection.
Consult your doctor
Please inform your doctor if you have kidney impairment/kidney disease before receiving Hemlibra 30 mg Injection.
Safe if prescribed
Hemlibra 30 mg Injection is safe for children if prescribed by a doctor. The dose and duration may vary depending on the child’s weight and the severity of the child's medical condition.
Caution
Please inform your doctor if you have heart problems before receiving Hemlibra 30 mg Injection, as there is limited information available on its safety in such cases.
Safe if prescribed
Hemlibra 30 mg Injection is generally safe for geriatric individuals. Please consult your doctor if you have any concerns.

Have a query?
Inform your doctor if you are using factor VIII or a bypassing agent, as these may increase the risk of blood clots, particularly when combined with activated prothrombin complex concentrate (aPCC). You may need to stop using bypassing agents or adjust their dosage as instructed by your doctor. Also, inform your doctor about any pre-existing medical conditions and all medications you are taking, including over-the-counter drugs, vitamins, and herbal supplements. Let your doctor know if you are pregnant or planning to become pregnant.
Login/Sign Up
Login/Sign Up
Hemlibra 30 mg Injection belongs to the group of medications called Monoclonal antibodies used to prevent or reduce bleeding episodes in individuals with haemophilia A, a genetic bleeding disorder caused by a clotting factor VIII deficiency.
Hemlibra 30 mg Injection contains Emicizumab. It replicates the function of factor VIII, a crucial protein for blood clotting. It connects activated factor IX and factor X, promoting effective clot formation in individuals with hemophilia A. This process helps prevent and minimize bleeding episodes, including in patients with factor VIII inhibitors.
If you use Hemlibra 30 mg Injection with a bypassing agent and if you experience confusion, weakness, vomiting, stomach or back pain, less urination, chest pain, trouble breathing, coughing blood, fast heartbeat, swelling or redness in your arms or legs, eye pain, or vision issues, contact your doctor immediately.
Hemlibra 30 mg Injection may cause common side effects like redness, tenderness, warmth, or itching at the injection site, joint pain, and headache. However, please consult your doctor if any of these side effects persist or worsen.
Disclaimer